Cytotoxicity and DNA Lesions Produced by Mitomycin C and Porfiromycin in Hypoxic and Aerobic EMT6 and Chinese Hamster Ovary...
... we have measured the cytotoxicity and DNA lesions produced by the bioreductive alkylating agents mitomycin C and porfiromycin, ... Mitomycin C and porfiromycin caused the same amount of cross-linking under conditions of oxygen deficiency; however, mitomycin ... Mitomycin C and porfiromycin were preferentially cytotoxic to hypoxic EMT6 cells in culture, with porfiromycin producing a ... DNA interstrand cross-links were observed in hypoxic EMT6 cells throughout a 24-h period following removal of mitomycin C and ...http://cancerres.aacrjournals.org/content/46/8/3939
Predicting Tumor Responses to Mitomycin C on the Basis of DT-Diaphorase Activity or Drug Metabolism by Tumor Homogenates:...
Bioreductive activation of mitomycin C. Cancer Metastasis Rev., 12: 83-101, 1993. ... Pan S-S., Andrews P. A., Glover C. J., Bachur N. R. Reductive activation of mitomycin C and mitomycin C metabolites by NADPH- ... Siegel D., Gibson N. W., Preusch P. C., Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C induced DNA ... Mitomycin resistance in mammalian cells expressing the bacterial mitomycin C resistance protein MCRA. Proc. Natl. Acad. Sci. ...http://cancerres.aacrjournals.org/content/60/22/6384
Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5...
Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development ... Tomasz M, Palom Y. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of ... Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin North Am. 2003;12:771-80.CrossRefGoogle Scholar ... Current issues in the enzymology of mitomycin C metabolic activation. Gen Pharmacol. 1998;1998/10/29:539-44.CrossRefGoogle ...https://rd.springer.com/article/10.1245/s10434-016-5665-6
Repair of mitomycin C mono- and interstrand cross-linked DNA adducts by UvrABC: a new model
8. Tomasz M, Palom Y. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis ... Repair of mitomycin C mono- and interstrand cross-linked DNA adducts by UvrABC: a new model. Mao-wen Weng,1 Yi Zheng,1 Vijay P ... Mitomycin C induces both MC-mono-dG and cross-linked dG-adducts in vivo. Interstrand cross-linked (ICL) dG-MC-dG-DNA adducts ... Mitomycin C can further form an intrastrand biadduct at -GG- sites and an interstrand cross-linked (ICL) dG-MC-dG lesion at a - ...http://pubmedcentralcanada.ca/pmcc/articles/PMC2978355/
Who can trade binary options for me
1997) The mitomycin bioreductive antitumor agents cross-linking and alkylation of DNA as the molecular basis of their activity ...http://imbc-med.ru/who-can-trade-binary-options-for-me.html
Compositions and Methods for Inducing Apoptosis in Prostate Cancer Cells - Patent application
... bioreductive alkylators such as mitomycin, procarbazine, dacarbazine and altretamine); DNA strand-breakage agents (e.g., ...http://www.patentsencyclopedia.com/app/20120237533
Diagnostic and Prognostic Markers for Cancer - Patent application
... bioreductive alkylators such as mitomycin, procarbazine, dacarbazine and altretamine); DNA strand-breakage agents (e.g., ...http://www.patentsencyclopedia.com/app/20130012409
SUBSTITUTED 1,3-CYCLOPENTADIONE MULTI-TARGET PROTEIN KINASE MODULATORS OF CANCER, ANGIOGENESIS AND THE INFLAMMATORY PATHWAYS...
... bioreductive alkylator, such as Mitomycin, and Procarbazine, Dacarbazine and Altretamine; antimetabolites, including folate ...http://www.patentsencyclopedia.com/app/20100137449
Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: Results of EORTC (First...
... there was no correlation between both Glut-1 and pimonidazole scores and T/C obtained for the bioreductive drug mitomycin C. ... sections of xenograft samples to detect expression of the intrinsic hypoxia marker Glut-1 and adducts of the bioreductive ...http://researchonline.ljmu.ac.uk/2336/
Thioredoxin-like domains required for glucose regulatory protein 58-mediated reductive activation of mitomycin C leading to DNA...
Bioreductive drugs play a significant role in the treatment of tumors of different organs. Bioreductive drug development is ... Molecular characterization of mitomycin C-induced large deletions and tandem-base substitutions in the bone marrow of gptδ ... These include mitomycin C (MMC), indoloquinone, 2,5-diaziridinyl-1,4-benzoquinone (DZQ), and 5-[aziridin-1-yl]-2,4- ... Naylor MA, Thomson P. Recent advances in bioreductive drug targeting. Mini Rev Med Chem 2001;1:17-29. ...http://mct.aacrjournals.org/content/6/10/2719
SpringerExemplar - mitomycin - Scientific Language Search
Summary The bioreductive alkylating agent. mitomycin Cytotoxicity of mitomycin C on clonogenic human carcinoma cells is not ... mitomycin Cardiotoxicity of mitomycin A, mitomycin C, and seven. N. 7. analogs in vitro. Cardiotoxicity of mitomycin A, ... mitomycin Phase I study of mitomycin C and menadione in advanced solid tumors. Phase I study of mitomycin C and menadione in ... mitomycin Pharmacokinetics of mitomycin C in rabbit and human. Pharmacokinetics of mitomycin C in rabbit and human. Hazel, Guy ...http://springerexemplar.com/search.aspx?q=mitomycin&val=publication%3ACancer+Chemotherapy+and+Pharmacology
SpringerExemplar - mitomycin - Scientific Language Search
mitomycin Bioreductive Prodrugs for Cancer Therapy. Bioreductive Prodrugs for Cancer Therapy. Seddon, Beatrice; Kelland, Lloyd ... mitomycin Five-year results of trabeculectomy with mitomycin C. Five-year results of trabeculectomy with mitomycin C. Beckers, ... mitomycin Foreign body granulomas secondary to retained sponge fragment following mitomycin C trabeculectomy. Foreign body ... mitomycin Collagen matrix vs mitomycin-C in trabeculectomy and combined phacoemulsification and trabeculectomy: a randomized ...http://springerexemplar.com/search.aspx?q=mitomycin&P=5
Impact on the Corneal Endothelium of Mitomycin C During Photorefractive Keratectomy
Mitomycin C by itself is non-reactive with DNA and after entering the cell must undergo bioreductive enzymatic activation. ... MECHANISM OF ACTION OF MITOMYCIN C. Mitomycin C is an antibiotic derived from Streptomyces caespitosus and is generally ... Toxic effects of mitomycin-C on cultured corneal keratocytes and endothelial cells. J Ocul Pharmacol Ther. 1999;15:401-411. [ ... Concentrations of mitomycin C in rabbit corneal tissue and aqueous humor after topical administration. Cornea. 2006;25:S20-S23. ...http://pubmedcentralcanada.ca/pmcc/articles/PMC2876307/
Mitomycin C - Wikipedia
Potential bis-alkylating heterocylic quinones were synthetised in order to explore their antitumoral activities by bioreductive ... Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour activity. It is given ... Mitomycin is also used as a chemotherapeutic agent in glaucoma surgery. Kersey JP, Vivian AJ (Jul-Sep 2008). "Mitomycin and ... Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is ...https://en.wikipedia.org/wiki/Mitomycin_C
Potentiation of Mitomycin C and Porfiromycin Antitumor Activity in Solid Tumor Models by Recombinant Human Interleukin 1α |...
The combinations also produced marked decreases in the yield of viable tumor cells, suggesting that the bioreductive drugs may ... Potentiation of Mitomycin C and Porfiromycin Antitumor Activity in Solid Tumor Models by Recombinant Human Interleukin 1α. Paul ... Potentiation of Mitomycin C and Porfiromycin Antitumor Activity in Solid Tumor Models by Recombinant Human Interleukin 1α ... Potentiation of Mitomycin C and Porfiromycin Antitumor Activity in Solid Tumor Models by Recombinant Human Interleukin 1α ...http://cancerres.aacrjournals.org/content/51/20/5454
DT-Diaphorase as a Critical Determinant of Sensitivity to Mitomycin C in Human Colon and Gastric Carcinoma Cell Lines | Cancer...
To study the bioreductive enzymes responsible for MMC activation in tumor cells, we examined the enzyme activities of DT- ... DT-Diaphorase as a Critical Determinant of Sensitivity to Mitomycin C in Human Colon and Gastric Carcinoma Cell Lines. Koji ... Mitomycin C (MMC), a known cytotoxic agent, requires cellular enzyme-mediated activation for effective antitumor activity. ... DT-Diaphorase as a Critical Determinant of Sensitivity to Mitomycin C in Human Colon and Gastric Carcinoma Cell Lines ...http://cancerres.aacrjournals.org/content/56/12/2823
Protocols and Video Articles Authored by Mark De Ridder (Translated to Russian)
... mitomycin C and tirapazamine). A meta-analysis of all randomized trials in which some form of hypoxic modification was ... and bioreductive drugs, which undergo intracellular reduction to form active cytotoxic species under low oxygen tension (e.g. ...https://www.jove.com/author/Mark_De+Ridder?language=Russian
Apaziquone - Wikipedia
... is an indolequinone that is a bioreductive prodrug and a chemical analog of the older chemotherapeutic agent mitomycin C. In ...https://en.wikipedia.org/wiki/Apaziquone
Kenneth B. Roberts, MD > Yale Cancer Center | Yale School of...
During my first ten years on the Yale faculty, I participated in clinical trials evaluating the efficacy of bioreductive ... A Phase III study comparing radiotherapy alone with radiotherapy plus Mitomycin C for cervix cancer has been completed in ... Venezuela with results showing a significant improvement in disease-free survival with the addition of Mitomycin C, which is a ...http://yalecancercenter.org/research/people/kenneth_roberts-2.profile
Effects of hypoxia on human cancer cell line chemosensitivity | BMC Cancer | Full Text
Mitomycin c. Quinone antibiotics. Bioreductive in hypoxia in murine sarcoma and mammary cell lines ... The effect of drugs generally more effective in oxygen deprived environment. Cisplatin (A and B), mitomycin c (C and D) and ... In general cisplatin, mitomycin c and tirapazamine (Figure 1) were more effective in anoxic or hypoxic environment (e.g. ... Schwartz HS: Pharmacology of mitomycin C. III. In vitro metabolism by rat liver. J Pharmacol Exp Ther. 1962, 136: 250-258. ...https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-331
CiNii 論文 - Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu...
Metabolism of mitomycin C by DT-diaphorase : role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma ... Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and ... Non-enzymatic and enzymatic activation of mitomycin C : identification of a unique cytosolic activity JOSEPH P. ... Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine ...https://ci.nii.ac.jp/naid/10008052934
Siegel D, Gibson NW, Preusch PC, Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and ... and formation of these species will depend on the levels of bioreductive enzymes. Among the bioreductive enzymes expressed in ... Beall HD, Mulcahy RT, Siegel D, Traver RD, Gibson NW, Ross D. Metabolism of bioreductive antitumor compounds by purified rat ... We have examined the role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the bioreductive metabolism of 17-allylamino- ...http://cancerres.aacrjournals.org/content/65/21/10006
Indian Patents. 252132:'A SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVE OF FORMULA (I)'
... mitomycin C, RSU 1069, SR 4233, EO9, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5- iododeoxyuridine (lUdR), ... mimicking oxygen or alternatively behave like bioreductive agents under hypoxia; non-hypoxic cell radiosensitizers (e.g., ...http://www.allindianpatents.com/patents/252132-a-substituted-2-alkyl-quinazolinone-derivative-of-formula-i
SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS - Patent application
... mitomycin C, RSU 1069, SR 4233, EO9, RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5-iododeoxyuridine (IUdR), ... mimicking oxygen or alternatively behave like bioreductive agents under hypoxia; non-hypoxic cell radiosensitizers (e.g., ...http://www.patentsencyclopedia.com/app/20110077245